ARAVライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 1月 2024 @ 06:00):

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States...

Stats
本日の出来高	4.04M
平均出来高	2.24M
時価総額	2.95M
EPS	$0 ( 2024-03-20 )
次の収益日	( $0 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0528
ATR14	$0.0130 (32.42%)

Insider Trading

Date	Person	Action	Amount	type
2023-04-10	Petrini Maria Carolina	Buy	400 000	Nonqualified Stock Option (Right to Buy)
2023-04-10	Petrini Maria Carolina	Buy	0
2023-02-01	Mcintyre Gail Frances	Buy	700 000	Stock Option (Right to Buy)
2023-02-01	Geller Robert B.	Buy	400 000	Stock Option (Right to Buy)
2023-02-01	Howard Rudy	Buy	400 000	Stock Option (Right to Buy)

INSIDER POWER
100.00
Last 91 transactions
Buy: 72 486 477 \| Sell: 119 333

ボリューム相関

長: 0.29 (neutral)

短: 0.00 (neutral)

Signal:(20.648) Neutral

Aravive Inc 相関

10 最も正の相関
ALXN	0.865
GENQ	0.848
BMAQ	0.847
ATNX	0.845
ROIV	0.843
TCMD	0.84
FXCO	0.84
OTEC	0.839
BRAC	0.839
ACAB	0.838

10 最も負の相関
EPSN	-0.867
GRIN	-0.853
MDGS	-0.853
FJP	-0.843
RFDI	-0.841
EWJV	-0.84
ALKS	-0.84
RNEM	-0.839
IFV	-0.837
PIII	-0.835

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Aravive Inc 相関 - 通貨/商品

-0.31
( neutral )

-0.78
( moderate negative )

0.00
( neutral )

-0.55
( weak negative )

0.89
( strong )

0.30
( neutral )

Aravive Inc 財務諸表

Annual	2022
収益:	$9.14M
総利益:	$-57.80M (-632.60 %)
EPS:	$-2.22

FY	2022
収益:	$9.14M
総利益:	$-57.80M (-632.60 %)
EPS:	$-2.22

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-2.48

FY	2020
収益:	$5.69M
総利益:	$0.00 (0.00 %)
EPS:	$-1.930

Financial Reports:

No articles found.

Aravive Inc

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics (Hong Kong) Limited to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.